Oncology Clinical Trials in Sioux Falls, SD

As of July 2026, 85 paid clinical trials are recruiting for Oncology in Sioux Falls, South Dakota. Oncology trials evaluate immunotherapies, targeted therapies, antibody-drug conjugates, and combination regimens across solid tumors and blood cancers — from early-phase first-in-human studies to phase 3 registration trials. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 17, 2026.

Filter results

Filter results

State

City

Facility

Recruitment status

Phase

Study type

Intervention

Condition

Sex

Age

Healthy volunteers only

86 clinical trials for Oncology

·Clear filters·↓ Download CSV

A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

for Biliary Tract Cancer

Drug: Rilvegostomig

Sites in Sioux Falls, Pierre +33 more locations

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT07221253·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

for Endometrial Cancer

Sites in Sioux Falls +65 more locations

Sponsor: AstraZeneca

Sex: Female·Age: 18+

Code: NCT07044336·Phase 3·Recruiting·Listed Jun 2025

Apply to this trial

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

for Endometrial Cancer

Drug: Rilvegostomig

Sites in Sioux Falls +44 more locations

Sponsor: AstraZeneca

Sex: Female·Age: 18+

Code: NCT06989112·Phase 3·Recruiting·Listed May 2025

Apply to this trial

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

for Non-small Cell Lung Cancer

Drug: Rilvegostomig

Sites in Sioux Falls +62 more locations

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT06692738·Phase 3·Recruiting·Listed Nov 2024

Apply to this trial

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

for Non-Small Cell Lung Cancer

Drug: Rilvegostomig

Sites in Sioux Falls +48 more locations

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT06357533·Phase 3·Recruiting·Listed Apr 2024

Apply to this trial

Conditions in Oncology (Sioux Falls, SD)

Breast cancer· 14 Non-small cell lung cancer (NSCLC)· 11 Ovarian cancer· 11 Solid tumor· 11 Endometrial cancer· 8 Cancer (any)· 5 Colorectal cancer· 4 Gastroesophageal junction cancer· 4 Fallopian tube cancer· 4 Acute myeloid leukemia (AML)· 4 Non-Hodgkin lymphoma· 4 Diffuse large B-cell lymphoma (DLBCL)· 4 Melanoma· 4 Metastatic breast cancer· 3 Esophageal cancer· 3 Chronic lymphocytic leukemia (CLL)· 3 Hematologic malignancy· 3 Head and neck cancer· 3 Neuroblastoma· 3 Triple-negative breast cancer· 2 Colon cancer· 2 Prostate cancer· 2 Kidney cancer· 2 Acute lymphoblastic leukemia· 2 Leukemia (other)· 2 Myelodysplastic syndromes (MDS)· 2 Hodgkin lymphoma· 2 Mantle cell lymphoma· 2 HER2-positive breast cancer· 1 HER2-negative breast cancer· 1 Lung cancer· 1 Rectal cancer· 1 Pancreatic cancer· 1 Gastric cancer· 1 Biliary tract cancer· 1 Gynecologic cancer· 1 Multiple myeloma· 1 Myeloproliferative neoplasm· 1 Follicular lymphoma· 1 Small lymphocytic lymphoma· 1 Burkitt lymphoma· 1 Sarcoma· 1 Osteosarcoma· 1 Ewing sarcoma· 1